All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

RBC Capital Markets Global Healthcare Conference 2026 May 19, 2026 10:00 AM EDTCompany ParticipantsLavina Talukdar - Senior VP ...

Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...

Key Points Interested in Candel Therapeutics, Inc.? Here are five stocks we like better. Candel Therapeutics said it remains ...

Could the new “7-minute cancer shot” mark a major shift in modern cancer care, making treatment faster, less exhausting and ...

Henry Schein, Inc. , the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced that its Board of Directors has elected William K. "Dan" ...

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...

Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...

Your brain isn't recording reality. It's predicting it. Understanding that one shift explains why psychedelics heal, why therapy matters, and why resistance isn't what we think.